Lyra Therapeutics, Inc.LYRANASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank15
Year-over-Year Change
Year-over-year research & development expense growth
Percentile
P15
Within normal range
vs 5Y Ago
-0.3x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -20.80% |
| Q2 2025 | 4.80% |
| Q1 2025 | -23.36% |
| Q4 2024 | 7.79% |
| Q3 2024 | -55.50% |
| Q2 2024 | -26.73% |
| Q1 2024 | 48.61% |
| Q4 2023 | -1.51% |
| Q3 2023 | 14.53% |
| Q2 2023 | -14.27% |
| Q1 2023 | 33.28% |
| Q4 2022 | -5.94% |
| Q3 2022 | -6.90% |
| Q2 2022 | 26.90% |
| Q1 2022 | -17.76% |
| Q4 2021 | 46.14% |
| Q3 2021 | -5.70% |
| Q2 2021 | 57.34% |
| Q1 2021 | 27.44% |
| Q4 2020 | 0.84% |
| Q3 2020 | 76.51% |
| Q2 2020 | -29.05% |
| Q1 2020 | -1.56% |
| Q4 2019 | 5.98% |
| Q3 2019 | -16.83% |
| Q2 2019 | 23.59% |
| Q1 2019 | 0.00% |